LUMIBIRD shares show a significant increase during Monday's trading session, rising by 5.58% compared to Friday's close at €22.70. This rebound occurs in a generally flat market environment, with major European indices showing no clear direction. No explicit catalyst — such as analyst recommendations, corporate announcements, or sector news — is evident from the available data to explain this movement.
LUMIBIRD shares increased by 5.58% during the session, reaching €22.70, up from a close of €21.50 on Friday. This movement sharply contrasts with the rest of the market: the CAC 40 is down 0.08% at 7,905.33 points, while the SBF 120 has decreased by 0.02% to 5,985.95 points. Thus, the rise in the stock occurs in complete disconnection with the general direction of the Parisian markets. Over the past seven days, the stock had still shown a decline of 4.22%, which puts today's gain in the context of a rebound after a recent correction. Over three months, the performance remains positive at 10.19%, and over a year, the stock has more than doubled, showing a gain of 119.3%.
Technical Perspective
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
From a technical standpoint, the previous days' decline had brought the stock close to the support level at €21.40, a level that Friday's close at €21.50 nearly touched. Today's rise appears as a rebound from this support zone. Additionally, the RSI was at 45 before this movement, in neutral territory, with no overbought or oversold signals, which technically does not hinder the continuation of the rebound. The 200-day moving average is at €19.91, well below the current price, while the 50-day moving average at €22.74 serves as a short-term reference level.
SectorMachines et équipements industriels›Photonique / lasers / instrumentation optique
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 114,7 millions d'euros
Quarterly revenue: 114,7 millions d'euros
Revenue growth: 7,4 %
EBITDA: 20 millions d'euros
Net income: 5,1 millions d'euros
Free cash flow: 2,3 millions d'euros
92,6 millions d'euros
Guidance from the release
« La croissance de la division Photonique, la progression de +20,2 % de son EBITDA et le niveau historiquement élevé de son carnet de commandes confortent la confiance du Groupe dans la poursuite de sa trajectoire de croissance rentable » — cession de Lumibird Medical à IPG Photonics prévue au T4 2026 (contrat signé début septembre, conditions suspensives en cours)
Risks mentioned
Recul de -16,2 % des activités Environnement, Topographie et Sécurité (5,2 M€)
Perturbations logistiques et géopolitiques ayant affecté le Médical au premier trimestre
Division Médical en retrait de -1,7 % en zone EMEA
Opportunities identified
Carnet de commandes à un niveau historiquement élevé offrant une excellente visibilité
Medtech Photonique en forte croissance (+58,3 %) sur les applications cardiovasculaires
Montée en puissance des grands programmes Défense & Spatial (+16,5 % à 29,4 M€)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.